1
|
Fabre M, Lamoureux A, Meunier L, Samaran Q, Lesage C, Girard C, Du Thanh A, Moulis L, Dereure O. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey. Melanoma Res 2024; 34:241-247. [PMID: 38546723 DOI: 10.1097/cmr.0000000000000963] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/26/2024]
Abstract
Although current systemic therapies significantly improved the outcome of advanced melanoma, the prognosis of patient with central nervous system (CNS) metastases remains poor especially when clinically symptomatic. We aimed to investigate the efficiency of CNS targets and tolerance of second-line combined anti-PD1/dual-targeted anti-BRAF/anti-MEK therapy implemented in patients with CNS progression after initially efficient first-line combined targeted therapy in patients with BRAF-mutated melanoma in a real-life setting. A monocentric retrospective analysis including all such patients treated from January 2017 to January 2022 was conducted in our tertiary referral center. The response of CNS lesions to second-line triple therapy was assessed through monthly clinical and at least quarterly morphological (according to RECIST criteria) evaluation. Tolerance data were also collected. Seventeen patients were included with a mean follow-up of 2.59 (±2.43) months. Only 1 patient displayed a significant clinical and morphological response. No statistically significant difference was observed between patients receiving or not additional local therapy (mainly radiotherapy) as to response achievement. Immunotherapy was permanently discontinued in 1 patient owing to grade 4 toxicity. Mean PFS and OS after CNS progression were 2.59 and 4.12 months, respectively. In this real-life survey, the subsequent addition of anti-PD1 to combined targeted therapy in melanoma patients with upfront CNS metastases did not result in significant response of CNS targets in most BRAF mutated melanoma patients with secondary CNS progression after initially successful first-line combined targeted therapy.
Collapse
Affiliation(s)
- Marie Fabre
- Department of Dermatology, University of Montpellier
| | | | | | | | | | - Céline Girard
- Department of Dermatology, University of Montpellier
| | - Aurélie Du Thanh
- Department of Dermatology, University of Montpellier
- INSERM U1058 'Pathogenesis and Control of Chronic and Emerging Infections' University of Montpellier, Montpellier, France
| | - Lionel Moulis
- Department of Dermatology, University of Montpellier
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier
- INSERM U1058 'Pathogenesis and Control of Chronic and Emerging Infections' University of Montpellier, Montpellier, France
| |
Collapse
|
2
|
Grolleau C, Calugareanu A, Demouche S, Nosbaum A, Staumont-Sallé D, Aubert H, Cassius C, Jachiet M, Saussine A, Bagot M, Bachelez H, Battistella M, Hotz C, Du Thanh A, Crépy MN, Bergerat D, Merandet M, Onifarasoaniaina R, Alberdi A, How-Kit A, Bouaziz JD, Le-Buanec H. IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis. J Invest Dermatol 2023; 143:711-721.e7. [PMID: 36610660 DOI: 10.1016/j.jid.2022.10.015] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2022] [Revised: 10/14/2022] [Accepted: 10/18/2022] [Indexed: 01/07/2023]
Abstract
Dupilumab is a therapeutic antibody targeting IL-4 and IL-13 receptor subunit alpha used for the treatment of patients with atopic dermatitis (AD). Cases of psoriasis-like reactions induced under dupilumab treatment (dupilumab-induced psoriatic eruption [DI-Pso]) for AD were recently reported. To understand the pathogenesis of DI-Pso, we performed gene expression profiling studies on skin biopsies of DI-Pso (n = 7) compared with those of plaque psoriasis, AD, and healthy controls (n = 4 each). Differential gene expression was performed using enrichment and Gene Ontology analysis. Gene expression was validated by qPCR, and protein levels were assessed by immunohistochemistry. Transcriptomic and protein analysis of DI-Pso compared with that of healthy controls, plaque psoriasis, and AD skins revealed activation of T helper 17/IL-23 pathways associated with a significant expression of IL-36, surrogate marker of pustular psoriasis. By contrast, T helper 2 representative genes' expression was strongly decreased in DI-Pso across comparison. Matching analysis with public data of pustular psoriasis skin corroborated that DI-Pso and pustular psoriasis upstream regulators overlap, greater than the overlap with plaque psoriasis. Furthermore, DI-Pso showed strongly decreased expression of many barrier skin genes compared with healthy controls, plaque psoriasis, and AD. Our data indicate that the pathogenesis of DI-Pso relied on a shift of skin immune responses from a T helper 2 to an IL-36 and T helper 17 polarization and on intensified skin barrier alterations.
Collapse
Affiliation(s)
- Chloé Grolleau
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Andreea Calugareanu
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France; Dermatology Department, University Hospital of Lyon, Lyon, France
| | - Sarah Demouche
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Audrey Nosbaum
- Dermatology Department, University Hospital of Lyon, Lyon, France
| | - Delphine Staumont-Sallé
- Dermatology Department, U1286 Inserm Lille Inflammation Translational Research Institute, University of Lille, Lille, France
| | - Hélène Aubert
- Dermatology Department, University Hospital of Nantes, Nantes, France
| | - Charles Cassius
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Marie Jachiet
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Anne Saussine
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Martine Bagot
- Dermatology Department, Saint Louis Hospital, Paris, France
| | - Hervé Bachelez
- Dermatology Department, Saint Louis Hospital, Paris, France; Laboratory of Genetic of Skin Diseases, INSERM U1163, Imagine Institute, University of Paris, Paris, France
| | | | - Claire Hotz
- Dermatology Department, Henri Mondor Hospital, Créteil, France
| | - Aurélie Du Thanh
- Dermatology Department, University Hospital of Montpellier, Montpellier, France
| | - Marie-Noëlle Crépy
- Dermatology Department, Paris University Hospital of Cochin, Paris, France
| | - David Bergerat
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | - Marine Merandet
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| | | | - Antonio Alberdi
- Technological Platerform of Saint- Louis Research Institute (IRSL), Saint-Louis Hospital, University of Paris, Paris, France
| | - Alexandre How-Kit
- Laboratory of Genomics, Foundation Jean Dausset (CEPH), Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, Saint Louis Hospital, Paris, France; Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France.
| | - Hélène Le-Buanec
- Saint-Louis Research Institute, INSERM U976 - HIPI Unit, University of Paris, Paris, France
| |
Collapse
|
3
|
Dandache E, Du Thanh A, Girard C, Bessis D, Dereure O. Evolution of Bullous Pemphigoid Clinical Pattern over Time: A 17-Year Single-Centre Retrospective Survey of 312 Cases. Dermatology 2022; 239:235-240. [PMID: 36481737 DOI: 10.1159/000527364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 10/01/2022] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Bullous pemphigoid (BP) clinical profile may have evolved during the last 2 decades. A retrospective, single-centre analysis investigated a possible shift of clinical presentation of the disease over time regarding both lesions' clinical pattern and locations and more particularly an increased frequency of characteristics considered as less classical regarding the usual clinical description of BP. PATIENTS AND METHODS Initial clinical data from all BP patients treated between January 2001 and April 2017 in a reference centre were collected and compared between four 4-year successive chronological subsets (G1 to G4). RESULTS 213/312 patients retained for final analysis (68.3%) displayed at least one initial non-classical characteristic, mainly head and neck, palmo-plantar, and/or mucosal involvement. Chronological analysis confirmed a significant increase over time of the percentage of patients displaying such features (G1 57.9% vs. G4 73.7%, p = 0.041). CONCLUSION Changes in BP clinical pattern may have occurred over the last two decades with the progressive emergence of forms with a number of less classical features. No significant clinical difference was observed between patients receiving or not DPP4 inhibitors at the time of diagnosis.
Collapse
Affiliation(s)
- Elise Dandache
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Aurélie Du Thanh
- Department of Dermatology, University of Montpellier, Montpellier, France.,INSERM U1058 Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Montpellier, France
| | - Céline Girard
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Didier Bessis
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France.,INSERM U1058 Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, Montpellier, France
| |
Collapse
|
4
|
Bouillet L, Fain O, Armengol G, Aubineau M, Blanchard-Delaunay C, Dalmas MC, De Moreuil C, Du Thanh A, Gobert D, Guez S, Hoarau C, Jaussaud R, Jeandel PY, Maillard H, Marmion N, Masseau A, Menetrey C, Ollivier Y, Pelletier F, Plu-Bureau G, Sailler L, Vincent D, Bouquillon B, Verdier E, Clerson P, Boccon-Gibod I, Launay D. Long-term prophylaxis in hereditary angioedema management: Current practices in France and unmet needs. Allergy Asthma Proc 2022; 43:406-412. [PMID: 35868842 DOI: 10.2500/aap.2022.43.220046] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Background: Hereditary angioedema (HAE) is characterized by unpredictable and potentially life-threatening attacks of cutaneous and submucosal swelling. Over the past decade, new agents, based on a better understanding of the underlying biologic mechanisms of HAE, have changed the face of long-term prophylaxis (LTP). Objective: The objective was to describe current practices and unmet needs with regard to LTP for HAE in expert centers in France. Methods: The study was conducted in France in 2020. Based on their experience with patients with HAE who had visited their center at least once in the past 3 years, physicians from 25 centers who are expert in the management of HAE were requested to fill in a questionnaire that encapsulated their active patient list, criteria for prescribing LTP, and medications used. They were asked about potential unmet needs with currently available therapies. They were asked to express their expectations with regard to the future of HAE management. Results: Analysis was restricted to 20 centers that had an active patient file and agreed to participate. There were 714 patients with C1 inhibitor (C1-INH) deficiency, of whom 423 (59.2%) were treated with LTP. Altered quality of life triggered the decision to start LTP, as did the frequency and severity of attacks. Ongoing LTP included androgens (28.4%), progestins (25.8%), lanadelumab (25.3%), tranexamic acid (14.2%), intravenous C1-INHs (5.6%), and recombinant C1-INH (0.7%). Twenty-nine percent of the patents with LTP were considered to still have unmet needs. Physicians' concerns varied among therapies: poor tolerability for androgens and progestins, a lack of efficacy for tranexamic acid and progestins, dosage form, and high costs for C1-INHs and lanadelumab. Physicians' expectations encompassed more-efficacious and better-tolerated medications, easier treatment administration for the sake of improved quality of life of patients, and less-expensive therapies. Conclusion: Despite the recent enrichment of the therapeutic armamentarium for LTP, physicians still expressed unmet needs with currently available therapies.
Collapse
Affiliation(s)
- Laurence Bouillet
- From the National Reference Center for Angioedema (CREAK), Department of Internal Medicine, Grenoble Alpes University, Laboratoire T-RAIG, UMR 5525 TIMC-IMAG (UGA-CNRS), Grenoble, France
| | - Olivier Fain
- Department of Internal Medicine, Sorbonne University, AP-HP, Saint Antoine Hospital, Paris, France
| | - Guillaume Armengol
- Department of Internal Medicine, Rouen University Hospital, Rouen, France
| | - Magali Aubineau
- Department of Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, France
| | | | - Marie-Caroline Dalmas
- Department of Internal Medicine, Hautepierre Hospital, Strasbourg University Hospital, France
| | - Claire De Moreuil
- Department of Internal Medicine, La Cavale Blanche University Hospital, Brest, France
| | - Aurélie Du Thanh
- Department of Dermatology, University Montpellier, Montpellier, France
| | - Delphine Gobert
- Department of Internal Medicine, Sorbonne University, AP-HP, Saint Antoine Hospital, Paris, France
| | - Stéphane Guez
- Allergy Diseases Unit, Internal Medicine and Post-Emergency, GH Pellegrin, Bordeaux University Hospital, Bordeaux, France
| | - Cyrille Hoarau
- Transversal Unit of Allergology and Clinical Immunology, Medicine Department, Tours Regional University Hospital, Tours University, France
| | - Roland Jaussaud
- Department of Internal Medicine and Clinical Immunology, Lorraine University, CHRU-Nancy, Nancy, France
| | - Pierre-Yves Jeandel
- Department of Internal Medicine, Nice University Hospital Center, Côte d'Azur University, Nice, France
| | - Hervé Maillard
- Dermatology Department, Le Mans Regional Hospital, Le Mans, France
| | - Nicolas Marmion
- Department of Medicine, Saint Louis University Hospital, Saint Pierre, Réunion
| | - Agathe Masseau
- Department of Internal Medicine, Nantes University Hospital, Nantes, France
| | | | - Yann Ollivier
- Department of Immuno-Allergology, Caen University Hospital, Caen, France
| | - Fabien Pelletier
- Department of Internal Medicine, Besancon University Hospital, Besancon, France
| | - Geneviève Plu-Bureau
- Department of Gynecology Obstetrics and Reproductive Medicine, Cochin University Hospital, Paris, France
| | - Laurent Sailler
- Internal Medicine, University Hospital Center Toulouse, Toulouse, France
| | - Denis Vincent
- Department of Internal Medicine, Nîmes University Hospital, Nîmes, France
| | | | | | | | - Isabelle Boccon-Gibod
- Department of Internal Medicine, CREAK, ACARE Center of Excellence, Grenoble Alpes University Hospital, France, and
| | - David Launay
- Department of Internal Medicine and Clinical Immunology, Lille University, Inserm, Lille University Hospital, CREAK, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France
| |
Collapse
|
5
|
Du Thanh A, Girard C, Morel J, Roubille C. Toward a holistic management of skin and joint disorders in PsA patients. Rheumatology (Oxford) 2021; 61:1310-1311. [PMID: 34850854 DOI: 10.1093/rheumatology/keab889] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Revised: 11/19/2021] [Accepted: 11/23/2021] [Indexed: 11/12/2022] Open
Affiliation(s)
- Aurélie Du Thanh
- Department of Dermatology, CHU Montpellier, Montpellier University, France.,Inserm 1058, pathogénèse et contrôle des infections chroniques, Montpellier, France
| | - Céline Girard
- Department of Dermatology, CHU Montpellier, Montpellier University, France
| | - Jacques Morel
- Department of Rheumatology, CHU Montpellier, Montpellier University, France
| | - Camille Roubille
- Department of Internal Medicine, CHU Montpellier, Montpellier University, Montpellier, France.,PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, cedex 5, France
| |
Collapse
|
6
|
Patras M, Decullier E, Lebbé C, Delyon J, Dantal J, Legendre C, Mazloum M, Du Thanh A, Boukari F, Morelon E, Jullien D, Kanitakis J, Ducroux E. Outcome of pretransplant melanoma after solid organ transplantation: an observational study. Transpl Int 2021; 34:2154-2165. [PMID: 34519106 DOI: 10.1111/tri.14109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2021] [Revised: 08/18/2021] [Accepted: 09/03/2021] [Indexed: 11/30/2022]
Abstract
The number of patients with a history of melanoma who are awaiting a solid organ transplantation (SOT) is increasing. Few recommendations exist on the timing to transplantation after melanoma diagnosis. The aim of this study was to assess the melanoma recurrence-free survival after pretransplant melanoma (PTM). We conducted a multicenter ambispective observational study. Organ transplant recipients (OTR) with a history of PTM and complete AJCC staging were included. Thirty-seven patients (predominantly men with a renal allograft) were included. Five melanomas were in situ, 21 stage IA, 4 stage IB, 5 stage II, and 2 stage IIIB. The median post-transplantation follow-up time was 4 years. Sixty-two percent of patients were followed up more than 2 years. Recurrence-free survival since melanoma reached 89.9%, but varied significantly according to AJCC staging (P = 0.0129). Three patients presented a recurrence. Despite the rather limited sample size and a wide range of follow-up, our findings concerning the recurrence-free survival appear reassuring for in situ and stage IA PTM; accordingly, we suggest that a waiting time to transplantation is not mandatory in patients with in situ or stage IA PTM, especially whenever SOT is urgently needed. Caution is, however, needed for patients with higher stage.
Collapse
Affiliation(s)
| | - Evelyne Decullier
- Service d'Epidémiologie et Recherches Cliniques, Pôle de Santé Publique, Hospices Civils de Lyon, Lyon, France
| | - Céleste Lebbé
- AP-HP Dermatology, INSERM U976, Saint Louis Hospital, Université de Paris, Paris, France
| | - Julie Delyon
- Service de Dermatologie, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France
| | - Jacques Dantal
- Service de Néphrologie, Hôpital Universitaire de Nantes, Hôtel Dieu, Nantes, France
| | - Christophe Legendre
- Service de Néphrologie et Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France
| | - Manal Mazloum
- Service de Néphrologie et Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France
| | - Aurélie Du Thanh
- Service de Dermatologie, Hôpital Universitaire de Montpellier, Montpellier, France
| | - Feriel Boukari
- Service de Dermatologie, Hôpital Universitaire de Nice, Nice, France
| | - Emmanuel Morelon
- Service de Néphrologie, Hôpital Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Denis Jullien
- Service de Dermatologie, Hôpital Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Jean Kanitakis
- Service de Dermatologie, Hôpital Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| | - Emilie Ducroux
- Service de Dermatologie, Hôpital Universitaire Edouard Herriot, Hospices Civils de Lyon, Lyon, France
| |
Collapse
|
7
|
Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Nosbaum A, Lasek A, Ferrier le Bouedec MC, Du Thanh A, Raison-Peyron N, Tetart F, Duval-Modeste AB, Misery L, Aubin F, Dompmartin A, Morice C, Droitcourt C, Soria A, Arnault JP, Delaunay J, Mahé E, Richard MA, Schoeffler A, Lacour JP, Begon E, Walter-Lepage A, Dillies AS, Rappelle-Duruy S, Barete S, Bellon N, Bénéton N, Valois A, Barbarot S, Sénéchal J, Staumont-Sallé D. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019; 81:143-151. [PMID: 30825533 DOI: 10.1016/j.jaad.2019.02.053] [Citation(s) in RCA: 136] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2018] [Revised: 02/17/2019] [Accepted: 02/22/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. OBJECTIVE We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. METHODS We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. RESULTS We included 241 patients. The median ± interquartile range (IQR) follow-up time was 3.8 ± 3.7 months. A ≥75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a ≥75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD ± IQR, 25 ± 21 vs 56 ± 27.4, P < 10-9 and EASI ± IQR, 4.1 ± 6.8 vs 17.9 ± 15.4, P < 10-9, respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (>500 cells/mm3) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10-6). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. LIMITATIONS No control group, missing data. CONCLUSION This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.
Collapse
Affiliation(s)
- Sarah Faiz
- CHU de Lille, Service de dermatologie, F-59000 Lille, France
| | - Jonathan Giovannelli
- CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France
| | - Céline Podevin
- Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France
| | - Marie Jachiet
- Dermatology Department, and Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France
| | - Jean-David Bouaziz
- Dermatology Department, and Université́ Paris Diderot Paris VII, Sorbonne Paris Cité APHP, Saint Louis Hospital, Paris, France
| | - Ziad Reguiai
- Service de dermatologie, Polyclinique Courlancy, Reims, France
| | - Audrey Nosbaum
- Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, University of Lyon, Lyon, France, CIRI (International Center for Infectiology Research), INSERM U1111, Ecole Normale Supérieure de Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Audrey Lasek
- Service de dermatologie, Hospital St Vincent de Paul, Groupement des Hôpitaux de l'Institut Catholique de Lille, France
| | | | - Aurélie Du Thanh
- Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
| | - Nadia Raison-Peyron
- Service de dermatologie, CHU Montpellier, Univ Montpellier, Montpellier, PCCI, INSERM, Univ Montpellier, Montpellier, France
| | - Florence Tetart
- Department of Dermatology, Inserm U519, Rouen University Hospital, Rouen, France
| | | | - Laurent Misery
- Department of Dermatology, University Hospital of Brest, Brest, France
| | - François Aubin
- Service de dermatologie, Centre Hospitalier Régional Universitaire de Besançon Université de Franche Comté, Besançon, France
| | - Anne Dompmartin
- Department of Dermatology, Caen University Hospital Center, France
| | - Cécile Morice
- Department of Dermatology, Caen University Hospital Center, France
| | - Catherine Droitcourt
- Service de Dermatologie, Centre Hospitalier Universitaire Pontchaillou, Université de Rennes, Rennes, France
| | - Angèle Soria
- Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France Sorbonne Universités Paris, Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
| | | | | | - Emmanuel Mahé
- Department of Dermatology, Hôpital Victor Dupouy Argenteuil, Argenteuil, France
| | - Marie-Aleth Richard
- Aix-Marseille University, EA 3279, CEReSS- Health Service Research and Quality of Life Center, Dermatology Department, Timone Hospital, Assistance Publique Hôpitaux de Marseille, 13385, France
| | - Amélie Schoeffler
- Service de Dermatologie, Hôpital Bel Air, Centre Hospitalier Régional Metz-Thionville
| | | | - Edouard Begon
- Service de Dermatologie, Centre Hospitalier René-Dubos, Pontoise, France
| | | | | | | | - Stéphane Barete
- Unité Fonctionnelle de Dermatologie, Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Paris, France
| | - Nathalia Bellon
- Service de Dermatologie, Hôpital Necker, AP-HP, Paris, France
| | | | - Aude Valois
- Service de Dermatologie, Hôpital d'Instruction des Armées Sainte Anne, Toulon, France
| | | | - Julien Sénéchal
- Service de Dermatologie, Centre de Référence des Maladies Rares de la Peau, Hôpital Saint André, CHU de Bordeaux, France; INSERM U1035 Biothérapie des Maladies Génétiques Inflammatoires et Cancers, Immuno-Dermatologie ATIP AVENIR, Université de Bordeaux, France
| | - Delphine Staumont-Sallé
- CHU de Lille, Service de dermatologie, F-59000 Lille, France; Univ Lille, INSERM U995, Lille Inflammation Research International Center, F-59000, Lille, France.
| | | |
Collapse
|
8
|
Schmaier AH, Cicardi M, Reshef A, Moldovan D, Mócsai A, López-Trascasa M, Lera AL, Brown NJ, Germenis AE, Filippelli-Silva R, Duarte DA, Martin RP, Veronez CL, Bouvier M, Bader M, Costa-Neto CM, Pesquero JB, Charest-Morin X, Marceau F, Rivard GÉ, Bonnefoy A, Wagner É, Debreczeni ML, Németh Z, Kajdácsi E, Schwaner E, Cervenak L, Oroszlán G, Szilágyi A, Dani R, Závodszky P, Gál P, Dobó J, Hébert J, Vincent M, Boursiquot JN, Chapdeleine H, Desjardins M, Laramée B, Gagnon R, Payette N, Lepeshkina O, Charignon D, Ghannam A, Ponard D, Drouet C, Joseph K, Tholanikunnel BG, Sexton DJ, Kaplan AP, Loffredo S, Bova M, Ferrara AL, Petraroli A, Suffritti C, Veszeli N, Zanichelli A, Farkas H, Marone G, Luyasu S, Favier B, Martin L, Kőhalmi KV, Temesszentandrási G, Várnai K, Varga L, Zuraw BL, Feussner A, Tortorici MA, Pawaskar D, Li HH, Anderson J, Bernstein JA, Zhang Y, Pragst I, Aygören-Pürsün E, Jacobson K, Christensen J, Van Leerberghe A, Wang Y, Schranz J, Martinez-Saguer I, Soteres D, Steiner U, Panovska VG, Rae W, Aberer W, Huissoon A, Bygum A, Magerl M, Graff J, Longhurst H, Lleonart R, Fang L, Cornpropst M, Clemons D, Mathis A, Collis P, Dobo S, Sheridan WP, Maurer M, Riedl MA, Craig T, Banerji A, Shennak M, Yang W, Baptista J, Busse P, Kalfus I, McDonald A, Qian S, Roberts A, Panousis C, Green T, Gille A, Zamanakou M, Loules G, Csuka D, Psarros F, Parsopoulou F, Speletas M, Firinu D, De Pasquale TMA, Zoli A, Radice A, Pizzimenti S, Manoussakis E, Konstantinou GN, Bafunno V, Montinaro V, Cancian M, Margaglione M, Bork K, Wulff K, Witzke G, Hardt J, Bouillet L, Caballero T, Grumach AS, Pommie C, Andresen I, Ettingshausen CE, Gutowski Z, Andritschke K, Linde R, Andrási N, Szilágyi T, Leibovich-Nassi I, Symons C, Dempster J, Boccon-Gibod I, Pagnier A, Lehmann A, Kreiberg KB, Nieto SA, Martins R, Martins R, Menendez A, Valle SOR, Olivares M, Hernandez-Landeros ME, Nievas E, Fili N, Barrera OM, Bailleau R, Gallardo-Olivos AM, Grau M, Rodriguez-Galindo J, Carabantes MJO, Zapata-Venegas E, Alfonso MM, Rosario-Grauert M, Ratti M, Vaszquez D, Josviack D, Landivar-Salinas LF, Calderón-Llosa OME, Campilay-Sarmiento R, Raby P, Fabiani J, Lumry WR, Feuersenger H, Watson DJ, Machnig T, Lamacchia D, Hernanz A, Alvez A, Lluncor M, Pedrosa M, Cabañas R, Prior N, Nordenfelt P, Nilsson M, Lindfors A, Wahlgren CF, Björkander J, Hakl R, Kuklínek P, Krčmová I, Hanzlíková J, Vachová M, Zachová R, Sobotková M, Strenková J, Litzman J, Palasopoulou M, Tsinti G, Gianni P, Kompoti M, Garrido S, Dyga W, Bogdali A, Obtułowicz A, Tomasz M, Czarnobilska E, Obtulowicz K, Książek T, Koncz A, Gulyás D, Staevska M, Jesenak M, Hrubiskova K, Bellizzi L, Relan A, Wu MA, Castelli A, Colombo R, Podda G, Del Medico M, Catena E, Casella F, Perego F, Afifi NA, Tobaldini E, Montano N, Sánchez-Jareño M, Stobiecki M, Obtułowicz K, Guryanova I, Polyakova E, Lebedz V, Salivonchik A, Aleshkevich S, Belevtsev M, Nordmann-Kleiner M, Trainotti S, Hahn J, Greve J, Zabrodska L, Alonso MLO, Tórtora RP, França AT, Ribeiro MG, Fu L, Kanani A, Lacuesta G, Waserman S, Betschel S, Espinosa MI, Contreras FA, Hrubisko M, Vavrova L, Banovcin P, Ayazi M, Fazlollahi MR, Saghafi S, Mohammadian S, Deshiry SN, Bidad K, Shoormasti RS, Mohammadzadeh I, Bemanian MH, Mahdaviani SA, Pourpak Z, Valerieva A, Vasileva M, Velikova T, Petkova E, Dimitrov V, Di Maulo R, Somech R, Golander H, Sifuentes EJ, Mansard C, Gompel A, Floccard B, Blanchard-Delaunay C, Launay D, Fain O, Sobel A, Gayet S, Amarger S, Armengol G, Ollivier Y, Zélinsky-Gurung A, Jeandel PY, Kanny G, Coppéré B, Dubrel M, Pelletier F, Du Thanh A, Trouiller S, Laurent J, De Moreuil C, Pajot CA, Belot A, Rodríguez A, Roa D, Prieto A, Baeza ML, Krusheva B, Almeida SKA, Constantino-Silva RN, Melo N, Simoes JA, Palma SMU, da Silva J, de Azevedo BF, Mansour E, González-Quevedo T, Marcos C, Lobera T, de San Pedro BS, Avilla E, Badiou J, Binkley K, Borici-Mazi R, Howlett L, Keith PK, Rowe A, Waite P, Billebeau A, Boccon-Gibbod I, Lis K, Laitman Y, Friedman E, Gokmen NM, Gulbahar O, Onay H, Koc ZP, Sin AZ. Abstracts from the 10th C1-inhibitor deficiency workshop. Allergy Asthma Clin Immunol 2017. [PMCID: PMC5496025 DOI: 10.1186/s13223-017-0198-5] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Reymann V, Girard C, Dereure O, Guillot B, Du Thanh A. Sporadic Porphyria in a patient with stage II melanoma treated with interferon α. Curr Drug Saf 2017; 12:CDS-EPUB-83200. [PMID: 28464763 DOI: 10.2174/1574886312666170502163628] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2017] [Revised: 01/16/2017] [Accepted: 03/08/2017] [Indexed: 11/22/2022]
Abstract
Porphyria cutanea tarda (PCT) is the most common form of human porphyria, due to reduced activity of uroporphyrinogen decarboxylase (UROD). There are many factors which can trigger PCT such as viral infections, excessive alcohol intake, iron overload, hepatotoxic drugs and hepatic tumours. Drug induced PCT is well documented but PCT induced by interferon α has rarely been described and only in cases of Hepatitis C Virus (HCV) infection or haematological malignancies. Here, we report the first case of de novo PCT induced by adjuvant interferon α (IFNα) therapy in a patient with stage II melanoma.
Collapse
|
10
|
Alsahli M, Debu A, Girard C, Bessis D, Du Thanh A, Guillot B, Dereure O. Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey–Hailey disease)? A series of eight patients. J DERMATOL TREAT 2017; 28:678-682. [DOI: 10.1080/09546634.2017.1308461] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Maha Alsahli
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Anca Debu
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Celine Girard
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Didier Bessis
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Aurélie Du Thanh
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Bernard Guillot
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| | - Olivier Dereure
- Department of Dermatology and INSERM, University of Montpellier, Montpellier, France
| |
Collapse
|
11
|
Du Thanh A, Martinez P, Cunat S, Bessis D, Guillot B, Dereure O. Absence of functional mutations in the ferroportin-encoding SLC40A1 gene in porphyria cutanea tarda: a series of 37 cases from southern France. Acta Derm Venereol 2011; 91:467. [PMID: 21607294 DOI: 10.2340/00015555-0987] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Du Thanh A, Aguilar-Martinez P, Cunat S, Bessis D, Guillot B, Dereure O. Hemojuvelin and hepcidin gene mutations in patients with porphyria cutanea tarda from Southern France. Acta Derm Venereol 2011; 91:66-7. [PMID: 21088809 DOI: 10.2340/00015555-0853] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|